Genprex (GNPX) Interest & Investment Income (2017 - 2024)
Genprex (GNPX) posted quarterly Interest & Investment Income of $4723.0 for Q4 2024, down 88.1% year-over-year from $39696.0 in Q1 2024, and down 41.55% quarter-over-quarter from $8080.0 in Q3 2024.
Genprex (GNPX) Interest & Investment Income (2017 - 2024) Analysis & Trends
Genprex's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $4723.0 for Q4 2024.
- In Q4 2024, Interest & Investment Income fell 88.1% year-over-year to $4723.0; the TTM figure through Dec 2024 stood at $63573.0 (down 70.45% YoY), while the FY2024 annual figure was $63574.0, down 70.45% from the prior year.
- Interest & Investment Income for Q4 2024 stood at $4723.0, down from $8080.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $68471.0 in Q1 2023, with the low at $879.0 in Q1 2021.
- The 5-year median for Interest & Investment Income is $6912.0 (2022), against an average of $19581.0.
- The sharpest annual moves came in 2021 and 2023: Interest & Investment Income sank 91.22% in 2021, then jumped 7689.65% in 2023.
- Genprex's Interest & Investment Income stood at $1344.0 in 2020, then fell by 26.56% to $987.0 in 2021, then jumped by 5533.03% to $55598.0 in 2022, then decreased by 28.6% to $39696.0 in 2023, then plunged by 88.1% to $4723.0 in 2024.
- Business Quant data shows GNPX's Interest & Investment Income at $4723.0 in Q4 2024, $8080.0 in Q3 2024, and $23057.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,723.00 |
| Sep 30, 2024 | 8,080.00 |
| Jun 30, 2024 | 23,057.00 |
| Mar 31, 2024 | 27,713.00 |
| Dec 31, 2023 | 39,696.00 |
| Sep 30, 2023 | 51,391.00 |
| Jun 30, 2023 | 55,550.00 |
| Mar 31, 2023 | 68,471.00 |
| Dec 31, 2022 | 55,598.00 |
| Sep 30, 2022 | 27,877.00 |
| Jun 30, 2022 | 5,744.00 |
| Mar 31, 2022 | 879.00 |
| Dec 31, 2021 | 987.00 |
| Sep 30, 2021 | 1,060.00 |
| Jun 30, 2021 | 1,104.00 |
| Mar 31, 2021 | 879.00 |
| Dec 31, 2020 | 1,344.00 |
| Sep 30, 2020 | 2,650.00 |
| Jun 30, 2020 | 4,811.00 |
| Mar 31, 2020 | 10,006.00 |